ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1178

Effect Of Febuxostat On Serum Urate Levels In Gout Subjects With Hyperuricemia and Moderate-To-Severe Renal Impairment: A Randomized Controlled Trial

Kenneth G. Saag1, Michael A. Becker2, Andrew Whelton3, Patricia A. MacDonald4, Yun Zhou5 and Lhanoo Gunawardhana5, 1Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 2Medicine, University of Chicago, Chicago, IL, 3The Johns Hopkins University and Universal Clinical Research Center, Inc., Baltimore, MD, 4Takeda Pharmaceuticals USA, Inc., Deerfield, IL, 5Takeda Global Research & Development Center, Inc., Deerfield, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Febuxostat and hyperuricemia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Up to 20% of patients with hyperuricemia (serum urate [sUA] >6.8 mg/dL) and gout have moderate-to-severe renal impairment. Higher sUA (>8.5 mg/dL) may increase the risk for progressive decline in renal function. The objective of this prospective 12-m pilot study was to evaluate the effect of treatment with febuxostat (FEB) vs placebo (PLB) on urate-lowering, renal function, and general safety in gout subjects with moderate-to-severe renal impairment.

Methods: In this multicenter, double-blind, phase 2 study, subjects were randomized 1:1:1 to receive 12 m of daily treatment with either FEB 30 mg BID, FEB 40/80 mg QD (titrated from 40 to 80 mg to achieve sUA <6.0 mg/dL) or PLB. Eligible subjects fulfilled ARA criteria for gout (subjects with tophi were excluded), had sUA >7.0 mg/dL, and had an estimated glomerular filtration rate (eGFR; by MDRD) ≥15 to ≤50 mL/min (severe, eGFR ≥15 to <30 mL/min; moderate, ≥30 to ≤50 mL/min) on d -21. Endpoints at m 12 included the proportion of subjects with sUA <6.0 mg/dL (Cochran-Mantel-Haenszel test) and change from baseline (CFB) in sUA and eGFR (by ANCOVA analysis). Adverse events (AEs) were recorded throughout the study.

Results: Among 96 subjects enrolled, 80% were male with a mean sUA (SD) of 10.5 (1.70) mg/dL; 95 subjects qualified for primary efficacy analysis. At m 1 visit, 20 subjects were titrated from FEB 40 mg to 80 mg QD based on d 14 sUA. At baseline, 28%, 31%, and 53% of subjects in the FEB 30 mg BID, FEB 40/80 mg QD, and PLB groups, respectively, had severe renal impairment. The proportion of subjects with sUA <6.0 mg/dL at m 12 was significantly greater in both FEB groups compared to PLB: 69%, 45%, and 0% for FEB 30 mg BID, FEB 40/80 mg QD, and PLB, respectively (p<0.001). The CFB in sUA at m 6 and m 12 was significantly greater in both FEB groups vs PLB (Table). Mean (SE) baseline eGFR was 34.14 (1.46), 34.08 (1.48), and 29.31 (1.46) mL/min/1.73 m².  Mean eGFR CFB (SE) at m 12 for FEB 30 mg BID and 40/80 mg QD (0.33 [1.17] and -0.86 [1.19] mL/min/1.73 m², respectively) was not significantly different from PLB (-2.05 [1.20] mL/min/1.73 m²; p>0.1). Overall, ≥1 AE was reported by 78%, 88%, and 78% of subjects in the FEB 30mg BID, FEB 40/80 mg QD, and PLB groups, respectively. The majority of AEs were mild to moderate in intensity and not considered to be related to study treatment. Elevated serum creatinine (increase from baseline ≥0.3 mg/dL) was seen in 13/32, 16/32, and 17/32 subjects in the FEB 30mg BID, FEB 40/80 mg QD, and PLB groups, respectively.  

Conclusion: In subjects with moderate-to-severe renal impairment, FEB urate-lowering was efficacious, with no emergent serious safety issues at 12 m. The sUA was significantly reduced in subjects receiving either regimen of FEB compared to PLB. CFB in renal function did not differ significantly between groups. Limitations include small sample size and a baseline imbalance in the distribution of subjects with severe vs moderate renal impairment across the treatment groups.

Table. CFB in serum urate

 

FEB 30 mg (N=32)

FEB 40/80 mg (N=31)

PLB (N=32)

 

LS mean (SE)

Baseline

10.36 (0.31)

10.35 (0.31)

10.72 (0.31)

CFB at m 6

-5.08 (0.30)*

-4.29 (0.31)*

0.07 (0.30)

CFB at m 12

-4.97 (0.32)*

-4.17 (0.32)*

-0.15 (0.32)

LS = least squares; SE = standard error; FEB = febuxostat; PLB = placebo; CFB = change from baseline; *p <0.001 vs PLB


Disclosure:

K. G. Saag,

Ardea, Takeda and BioCryst,

5,

Ardea, Savient, Takeda, and Regeneron,

2,

Ardea, Takeda and BioCryst ,

9;

M. A. Becker,

Takeda, Savient, Ardea Biosciences, AstraZeneca, BioCryst, URL/Mutual, Metabolex, Regeneron,

5,

UpToDate Inc.,

7;

A. Whelton,

Takeda Pharma,

5,

Takeda Speakers Bureau,

9;

P. A. MacDonald,

Takeda Global Research and Development Center ,

3;

Y. Zhou,

Takeda Global Research and Development Center, Inc.,

3;

L. Gunawardhana,

Takeda Global Research and Development Center, Inc.,

3,

Takeda Global Research and Development Center, Inc.,

4.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-febuxostat-on-serum-urate-levels-in-gout-subjects-with-hyperuricemia-and-moderate-to-severe-renal-impairment-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology